Phase II trial with triptorelin in prostatic carcinoma | Triptorelin / Decapeptyl / Trelstar | / | Publications

Menu Content/Inhalt

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Triptorelin / Decapeptyl / Trelstar

Phase II trial with triptorelin in prostatic carcinoma

A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma International Urology and Nephrology, 33:379-383, 2001).

full_paper_in.pdf